Brainstorm Cell Therapeutics Inc. (BCLI)

Market Cap	8.54M
Revenue (ttm)	n/a
Net Income (ttm)	-11.09M
Shares Out	7.91M
EPS (ttm)	-2.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,066,816
Open	1.080
Previous Close	1.080
Day's Range	1.000 - 1.120
52-Week Range	0.723 - 8.401
Beta	0.34
Analysts	Strong Buy
Price Target	30.00 (+2,677.78%)
Earnings Date	May 15, 2025

About BCLI

Brainstorm Cell Therapeutics Inc. a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the devel...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 27
• Stock Exchange: NASDAQ
• Ticker Symbol: BCLI
• Website: https://www.brainstorm-cell.com

Analyst Forecast

According to one analyst, the rating for BCLI stock is "Strong Buy" and the 12-month stock price forecast is $30.0.

Price Target

$30.0

(2,677.78% upside)

Analyst Consensus: Strong Buy